2886 research outputs found
Sort by
Cardiovascular Benefits of Beetroot Juice
No full textCardiovascular diseases (CVDs) are the leading cause of mortality and morbidity worldwide. According to the National Institutes of Health (NIH), researchers spent more than $2.88 billion on CVD research in the United States in 2023.1 While billions are spent primarily on research into pharmaceuticals, less attention is often paid to non-pharmaceutical, low-risk interventions such as dietary supplements. Beetroot juice, due to its high nitrate content, has increased in popularity due to its recent recognition as a super food which can improve cardiovascular health. When consumed, dietary nitrate is converted into nitric oxide (NO), a key regulator of vasodilation and blood flow. This article discusses recent findings about the cardiovascular benefits of beetroot juice, emphasizing its potential to lower blood pressure, enhance endothelial function, and improve lipid profiles. Patients with risk factors such as hypertension and metabolic syndrome show the most improvement in cardiovascular health. As with any intervention, healthcare providers must also consider potential risks such as increased nitrate intake and the formation of N-nitroso compounds. This review will provide healthcare providers with a balanced perspective on the role of beetroot juice as a preventive intervention for CVD
Navigating the Overlapping Landscapes of Smith-Lemli-Opitz Syndrome and Fetal Fentanyl Syndrome: Impacts on Neonatal Development
No full textSmith-Lemli-Opitz Syndrome (SLOS) and Fetal Fentanyl Syndrome (FFS) are both conditions that present with similar clinical features but have different pathophysiologies. SLOS is an autosomal recessive disorder resulting from a mutation in the DHCR7 gene, affecting the cholesterol synthesis pathway, ultimately leading to physical and cognitive impairments. FFS, is an emerging diagnosis that only presents with prenatal exposure to fentanyl. This exposure disrupts the same cholesterol synthesis pathway seen in SLOS, but unlike SLOS, it is not inherited. Instead, it is a developmental condition resulting from in utero opioid exposure,leading to similar physical characteristics due to the disruption of the same cholesterol pathway. FFS has become an emerging diagnosis within the more recent years secondary to the unfortunate rise in opioid use during pregnancy. If we can begin to understand the presentation and familiarize ourselves with the risk factors and varying presentations, we can significantly improve patient outcomes. This CME examines the mechanisms of disease for both SLOS and FFS, the various clinical displays and features, appropriate treatments, diagnostics, and education on the ability to provide the appropriate standard of care for this special patient population
Structural and Interpersonal Determinants of COVID-19 Vaccine Uptake in Vulnerable Populations of the United States
Get PDFSince its introduction in late 2020, the uptake of the COVID-19 vaccine has had the lowest rates in marginalized populations like minorities, elderly, and those of low socioeconomic status. Decreased rates of vaccination uptake in these groups has resulted in increased burden of disease and subsequently higher rates of hospitalization and death. Many inequities in poor COVID-19 health outcomes can be explained by examining common predictive factors that determine vaccination rates in these United States populations. This special article research aims to explore these various predictive factors with the goal to provide targeted strategies to boost COVID-19 vaccination rates, especially as the virus continues to evolve with new variants
My Heart Will Go On: A Look into Rechargeable Pacemaker Technology
No full textCurrently, all pacemaker batteries have a lifespan. Most are, on average, 10 years, but some can operate as long as 15 years before they need replacement. The act of replacing a pacemaker battery requires the patient be anesthetized and artificially paced in an operating-room setting. The major risk that this poses is that many patients who have pacemakers are elderly and/or high-risk patients with high mortality rates for what is supposed to be an otherwise simple procedure. The way to eliminate this mortality risk is through eliminating the need for surgery altogether, through implementation of rechargeable pacemakers. There is preliminary research in current medical literature that suggests concepts such as thermal energy recharging via body heat, or mag-safe style charging that hovers over the skin where the implant is, similar to current Apple iPhone charging technology. However, no clinical trials have begun yet to test these theories. This CME will summarize and explore current research in rechargeable pacemaker technology, as well as surmise how it might come into the market
Arcadia Magazine, 2025-01
No full texthttps://scholarworks.arcadia.edu/alumni_magazine/1133/thumbnail.jp
Arcadia Magazine, 2025-07
No full texthttps://scholarworks.arcadia.edu/alumni_magazine/1134/thumbnail.jp
10th Edition Introduction
Get PDFWe are proud to present the tenth annual issue of The Journal of International Relations, Peace Studies, and Development, produced in collaboration with the AGS International Graduate Student Conference 2025, “Trump 2.0: Reshuffling the International Deck.”
The reelection of Donald Trump has sent seismic shifts through the international order, challenging long-standing alliances, diplomatic norms, and the very architecture of global governance. This issue offers an urgent and critical examination of how a reinforced “America First” doctrine may redefine international relations, trade, security, and multilateral cooperation.
Set against a backdrop of escalating global crises—from climate change and armed conflict to systemic inequality—the articles collected here provide rigorous analysis of our most pressing challenges. Moving beyond diagnosis, the contributors propose actionable pathways for meaningful policy engagement, bridging the critical gap between academic research and real-world application.
Beyond the central focus on this new political era, the issue is rounded out by innovative research in key areas of research and a pertinent book review, collectively enriching the discourse on peace, justice, and global equity.
We invite scholars, policymakers, and engaged readers to explore these timely insights into the evolving dynamics of a world in flux
Pathway to Diagnosing and Managing Acute Aortic Dissection
No full textAcute Aortic Dissections (AAD) have historically been a debilitating and morbid diagnosis. With current advancements in medicine, one would think that mortality rates for AAD would be diminished, but this is not the case.1,2 The biggest factor associated with these deaths is the lack of an evidence-based pathway to diagnose and treat AAD.2 As the population increases in age, it is predicted that AAD will become a more common occurrence, and the need for this pathway will be vital.3 Even with current developments, the outcomes for these patients can be improved. With future research in noninvasive surgical techniques and laboratory diagnostics, such as biomarkers used to treat and diagnose this disease, it is anticipated that better interventions can be found to decrease mortality overall
Cardiac Amyloidosis: An Underdiagnosed Cause of Heart Failure
No full textCardiac amyloidosis (CA) is thought of as a rare cause of heart failure, although underdiagnosis makes its true prevalence difficult to discern. Advances in diagnosis have revealed that CA is likely more prevalent than once previously believed. Despite the advances in treatment for cardiac amyloidosis, prognosis remains poor. Early recognition of “red flags” reduces delays in diagnosis and treatment. Additionally, as incidence of CA increases, clinicians must understand the treatment of CA and how it differs from other forms of heart failure. This CME emphasizes different epidemiological features and “red flags” that may alert a clinician to screen for cardiac amyloidosis. It will then discuss the diagnostic workup and treatment for CA and its comorbidities
Ethical telemedicine use in post-pandemic healthcare
No full textProviding medical care to patients via telemedicine in the United States essentially became a standard of care practice due to the 2020 coronavirus (COVID-19) pandemic. While telemedicine was not new for the American healthcare system, the U.S. government had to dramatically relax legal restrictions to accommodate demand. Now that the pandemic is over, healthcare providers and medical organizations are left to decide if and how implementing telemedicine should continue. While telemedicine has increased access to care across gender, race, and economic status, patient safety and quality medical practices need to be maintained for telemedicine’s sustained success. This article discusses current legal, financial and ethical barriers to continued telemedicine utilization